Holen Sie sich die Stockscreener-App
12.18
2.40%
-0.30
Handel nachbörslich:
12.18
Arvinas Inc Aktie (ARVN) Neueste Nachrichten
Investor Mood: Can Arvinas Inc outperform in the next rally2026 Weekly Recap & Long-Term Safe Return Strategies - baoquankhu1.vn
Arvinas (NASDAQ:ARVN) Shares Down 7.8%What's Next? - MarketBeat
Arvinas to present ARV-102 Parkinson’s trial data at conference By Investing.com - Investing.com Nigeria
Arvinas, Inc. to Present Phase 1 Trial Data on ARV-102 for Parkinson’s Disease at AD/PD 2026 Conference - Quiver Quantitative
Arvinas to present ARV-102 Parkinson’s trial data at conference - Investing.com
Early ARV-102 Parkinson’s data to debut at Alzheimer’s-Parkinson’s conference - Stock Titan
Arvinas Highlights Phase 1 Shift, 2026 Data Catalysts, and Vepdegestrant NDA at Barclays Conference - MarketBeat
Arvinas (NASDAQ:ARVN) Sets New 12-Month High on Insider Buying Activity - MarketBeat
Arvinas Stock Pre-Market (+4.7%): Broad Biotech Rally on Geopolitical De-escalation, Falling Oil - Trefis
Arvinas Teases Near-Term Phase 1 Data, Eyes New Vepdegestrant Partner at Leerink Conference - MarketBeat
Insider Buying: Briggs Morrison Acquires 20,000 Shares of Arvinas Inc (ARVN) - GuruFocus
ARVN: Multiple phase I programs advance, with key data for LRRK2 and KRAS G12D degraders expected in 2024 - TradingView
Briggs Morrison Acquires 20,000 Shares of Arvinas (NASDAQ:ARVN) Stock - MarketBeat
Vanguard Group Inc. Trims Position in Arvinas, Inc. $ARVN - MarketBeat
Institution Moves: What dividend growth rate does Arvinas Inc offer2025 Macro Impact & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Why analysts remain bullish on Arvinas Inc. stock2025 Trading Recap & Accurate Buy Signal Alerts - Naître et grandir
Piper Sandler reiterates Arvinas stock rating on platform validation By Investing.com - Investing.com India
Piper Sandler reiterates Arvinas stock rating on platform validation - Investing.com South Africa
How The Arvinas (ARVN) Narrative Is Evolving With New Leadership And Key 2026 Pipeline Catalysts - Yahoo Finance
Discipline and Rules-Based Execution in ARVN Response - Stock Traders Daily
Arvinas (NASDAQ:ARVN) Given New $18.00 Price Target at Citigroup - MarketBeat
Citigroup Raises Price Target for Arvinas (ARVN) to $18.00 | ARV - GuruFocus
Arbiter Partners Capital Management LLC Invests $3.86 Million in Arvinas, Inc. $ARVN - MarketBeat
Arvinas Highlights Growing Phase 1 Pipeline, Near-Term Catalysts at TD Cowen Healthcare Conference - MarketBeat
ARVN: Multiple phase I programs advance with key data and commercialization milestones ahead - TradingView
ARVN: Multiple phase 1 programs advance with key data updates expected for LRRK2, BCL6, and KRAS - TradingView
Arvinas (NASDAQ:ARVN) Director John Houston Sells 35,297 Shares - MarketBeat
Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials - Insider Monkey
Arvinas (NASDAQ:ARVN) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
11 Best Cancer Stocks to Invest In Now - Insider Monkey
TD Cowen Health Care Conference - marketscreener.com
Arvinas Holding Company (ARVN) Gets a Hold from Morgan Stanley - The Globe and Mail
Arvinas, Inc. (ARVN) Stock Analysis: Navigating the 6.50% Upside Potential Amidst Clinical Innovations - DirectorsTalk Interviews
HC Wainwright Estimates Arvinas' Q1 Earnings (NASDAQ:ARVN) - MarketBeat
Arvinas outlines 2026 clinical data milestones and maintains cash runway into second half of 2028 amid strategic pipeline focus - MSN
Analysts Conflicted on These Healthcare Names: Akebia Therapeutics (AKBA), Idexx Laboratories (IDXX) and Arvinas Holding Company (ARVN) - The Globe and Mail
New CEO at local biotech firm is leading shift to early-stage drugs - Yale Daily News
Teel Randy, president and CEO of Arvinas, sells $58k in stock - Investing.com India
Arvinas CSO Cacace sells $43,885 in stock to cover tax obligations - Investing.com Australia
Arvinas chief accounting officer Loomis sells $13k in stock By Investing.com - Investing.com South Africa
Teel Randy, president and CEO of Arvinas, sells $58k in stock By Investing.com - Investing.com Australia
Arvinas chief accounting officer Loomis sells $13k in stock - Investing.com
Arvinas (NASDAQ:ARVN) CAO David Loomis Sells 1,108 Shares - MarketBeat
Arvinas (NASDAQ:ARVN) CEO Randy Teel Sells 4,786 Shares - MarketBeat
[Form 4] ARVINAS, INC. Insider Trading Activity - Stock Titan
5 Analysts Assess Arvinas: What You Need To Know - Benzinga
Arvinas (NASDAQ:ARVN) Trading Up 9%Still a Buy? - MarketBeat
Arvinas (NASDAQ:ARVN) Receives Overweight Rating from Piper Sandler - MarketBeat
Piper Sandler Raises Price Target on Arvinas (ARVN) to $20.00 | - GuruFocus
ARVN: Evercore ISI Raises Price Target to $19, Maintains Outperf - GuruFocus
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):